Caris Life Sciences, Inc.
CAI
$37.90
-$0.58-1.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 81.31% | 49.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 81.31% | 49.88% | |||
| Cost of Revenue | 8.35% | 17.02% | |||
| Gross Profit | 202.72% | 118.51% | |||
| SG&A Expenses | 33.65% | 9.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.35% | 3.45% | |||
| Operating Income | 73.16% | 37.16% | |||
| Income Before Tax | -8.47% | 7.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.47% | 7.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.47% | 7.61% | |||
| EBIT | 73.16% | 37.16% | |||
| EBITDA | 79.10% | 31.69% | |||
| EPS Basic | -213.88% | 6.12% | |||
| Normalized Basic EPS | 55.66% | 8.41% | |||
| EPS Diluted | -213.88% | 6.12% | |||
| Normalized Diluted EPS | 55.66% | 8.41% | |||
| Average Basic Shares Outstanding | 83.54% | 0.88% | |||
| Average Diluted Shares Outstanding | 83.54% | 0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||